
News


In addition to the educational offerings, the program offers opportunities for relaxation and spiritual and family-building events.

Novel concept: inner choroid/outer retina neurovascular unit

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

Of the 484 hospitals, 22 are named to the national Honor Roll for ranking in one or more of the specialties that US News evaluates.

At the 2023 ASRS annual meeting in Seattle, Washington, Michael Singer, MD, spoke with our team about the Starlight Study, which is an optogenetic study looking at patients who had Stargardt disease.

Michael Singer, MD, spoke with our team about the Starlight Study, an optogenetic study looking at patients who had Stargardt's disease at the 2023 ASRS annual meeting. At the meeting, Nanoscope Therapeutics Inc presented key results from its STARLIGHT Phase 2 clinical trial.


OSC-01 is a novel, high concentration preservative-free topical OPTIREACH formulation of dexamethasone.

Aleksandra Rachiskaya, MD, a member of the Modern Retina advisory board, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept in recent studies at the 2023 ASRS annual meeting.

The Summit will inspire and enable attendees to achieve their goals via a multi-pronged approach.

The gene therapy company announces its closure less than 2 years after the company launch in 2021.

Aleksandra Rachiskaya, MD, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept at the 2023 ASRS annual meeting.

Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of July 30, 2023.

According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.

According to the company, the solution slowed the loss of photoreceptors and disease progression as early as six months.

Nancy Lurker, spoke with our team about the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 at the 2023 ASRS annual meeting.

Paul Hahn, MD, PhD, spoke with our team about comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy at the 2023 ASRS annual meeting.

Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 with our team at the 2023 ASRS annual meeting.

Prevent Blindness has declared the month of August Children’s Eye Health and Safety Month. The goal of this initiative is to educate parents and caregivers on ways to keep children’s eyes healthy.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, shared the latest information on the GALE extension study.

The program was created based on direct requests to CHCP by local employers, led by UT Southwestern Medical Center, who noted a high need for skilled ophthalmology assistants.

The trial is a prospective, multi-center, open label, single-armed trial which plans on enrolling 24 eligible subjects with cystoid macular edema.

Even when wearing their glasses or contact lenses, individuals who scored worse on vision tests were also more likely to have concerning scores on cognitive tests.

This year’s meeting will include boxing rings, ball gowns and a full schedule of engaging new symposia

President and CEO at Outlook Therapeutics, Russ Trenary, shared an update on the company's work toward FDA approval for Bevacizumab with our team at the 2023 ASRS annual meeting.

Russ Trenary, President and CEO at Outlook Therapeutics spoke with our team to share information on the company's work toward FDA approval for Bevacizumab at the 2023 ASRS annual meeting.

Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.

Study determines female ophthalmology students were less likely to ask questions during grand rounds
The main finding was that the male grand round attendees were more likely to pose 1 of the first 3 questions compared with female attendees.
